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Diabetes is a chronic metabolic disease characterized by hyperglycemia in the absence
of treatment. Among the diabetes-associated complications, cardiovascular disease is
the major cause of mortality and morbidity in diabetic patients. Diabetes causes a
complex myocardial dysfunction, referred as diabetic cardiomyopathy, which even in the
absence of other cardiac risk factors results in abnormal diastolic and systolic function.
Besides mechanical abnormalities, altered electrical function is another major feature of
the diabetic myocardium. Both type 1 and type 2 diabetic patients often show cardiac
electrical remodeling, mainly a prolonged ventricular repolarization visible in the
electrocardiogram as a lengthening of the QT interval duration. The underlying
mechanisms at the cellular level involve alterations on the expression and activity of
several cardiac ion channels and their associated regulatory proteins. Consequent
changes in sodium, calcium and potassium currents collectively lead to a delay in
repolarization that can increase the risk of developing life-threatening ventricular
arrhythmias and sudden death. QT duration correlates strongly with the risk of
developing torsade de pointes, a form of ventricular tachycardia that can degenerate
into ventricular fibrillation. Therefore, QT prolongation is a qualitative marker of
proarrhythmic risk, and analysis of ventricular repolarization is therefore required for
the approval of new drugs. To that end, the Thorough QT/QTc analysis evaluates QT
interval prolongation to assess potential proarrhythmic effects. In addition, since diabetic
patients have a higher risk to die from cardiovascular causes than individuals without
diabetes, cardiovascular safety of the new antidiabetic drugs must be carefully evaluated
in type 2 diabetic patients. These cardiovascular outcome trials reveal that some
glucose-lowering drugs actually reduce cardiovascular risk. The mechanism of
cardioprotection might involve a reduction of the risk of developing arrhythmia.
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INTRODUCTION
Diabetes affected 422 million adults in 2014 (WHO, 2021), but the incidence and the associated
socio-sanitary cost are steadily rising. Diabetes is a chronic metabolic disease characterized by
hyperglycemia in the absence of treatment. Type 1 diabetes (T1D), caused by insufficient or no
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the cases and starts with insulin resistance, but later progresses
towards various degrees of β-cell dysfunction. As a result, many
type 2 diabetic patients may need exogenous insulin.
In the last decades, available pharmacologic approaches have
significantly improved the life span and the quality of life of
diabetic patients. However, over time, diabetes-associated
complications have emerged. Among them, cardiovascular
disease stands out because is the major cause of mortality and
morbidity in diabetic patients. In fact, the Framingham study
reported that patients with type 2 diabetes were twice as likely as
healthy people to die from cardiovascular diseases (Kannel et al.,
1974). Currently, due to the advances in diabetes management,
many diabetic patients achieve good glycemic control. However,
cardiovascular complications remain (Food and Drug
Administration, 2008; Duckworth et al., 2009) and are still the
leading cause of death (Preis et al., 2009; Xu and Rajaratnam,
2017).
Besides inducing cardiovascular disease, diabetes changes the
myocardial structure leading to a cardiac dysfunction known as
diabetic cardiomyopathy. Diabetic cardiomyopathy was first
described by Rubler et al., in 1972 as heart failure in diabetics
without hypertension, myocardial ischemia, congenital or
valvular disease (Rubler et al., 1972). It is currently defined as
a ventricular dysfunction in the absence of coronary artery
disease or hypertension (Bugger and Abel, 2014). In fact, the
Framingham study described the association between diabetes
and cardiac hypertrophy independently from blood pressure
(Kannel et al., 1974). Moreover, the Cardiovascular Health
study (Lee et al., 1997) and the Strong Heart study (Devereux
et al., 2000) confirmed the association between diabetes and
increased left ventricular mass and wall thickness with
compromised diastolic and systolic function. Different
mechanisms have been proposed to promote the development
of diabetic cardiomyopathy and damage the heart. These include
cardiac insulin resistance; metabolic remodeling with abnormal
free fatty acids metabolism and lipotoxicity; mitochondrial
dysfunction with increased ROS production; accumulation of
advanced glycation end products and collagen; abnormalities in
calcium handling; pro-inflammatory responses; activation of the
renin-angiotensin-aldosterone system and autonomic
neuropathy with increased sympathetic activity (reviewed in
Casis and Echevarria, 2004; Battiprolu et al., 2013; Bugger and
Abel, 2014; Onay-Besikci, 2014; Grisanti, 2018; Jia et al., 2018;
Palomer et al., 2018; Quagliariello et al., 2020).
Torsade de pointes (TdP) is a ventricular arrhythmia
characterized by a change in the amplitude and a twisting of
the QRS complexes around the isoelectric line in the
electrocardiogram. TdP usually ends spontaneously, but in
some cases may degenerate into lethal ventricular fibrillation.
Long QT syndrome is an inherited or drug-induced arrhythmia
syndrome characterized by a prolongation of the QT interval
(Sanguinetti and Tristani-Firouzi, 2006; Schwartz et al., 2012)
that causes torsade de pointes, ventricular fibrillation and sudden
death. Since TdP occurs in the setting of prolonged QT intervals,
QT duration and heart rate-corrected QT duration (QTc) have
become qualitative markers of proarrhythmic risk. The
electrocardiogram of both type 1 and type 2 diabetic patients
often shows prolonged QT (Bellavere et al., 1988; Chambers et al.,
1990; Jermendy et al., 1990; Ewing et al., 1991; Veglio et al., 2000;
Brown et al., 2001; Ninkovic et al., 2016), which increases the risk
of ventricular arrhythmia (Tse et al., 2016; Hegyi et al., 2019). At
the cellular level, diabetes lengthens the cardiac action potential
duration due to changes in the expression and
electrophysiological properties of various ion channels
(Lengyel et al., 2007; Torres-Jacome et al., 2013; Gallego and
Casis, 2014).
In addition, arrhythmogenesis in diabetes might be amplified
by other factors like autonomic dysregulation (Jermendy, 2003;
Spallone et al., 2011; Chen et al., 2019), inflammation (Karam
et al., 2017) and the presence of comorbidities such as
hypertension (Yiu and Tse, 2008). This review focuses on the
electrical characteristics of the diabetic myocardium, such as
reduced conduction velocity and prolonged ventricular
repolarization. Since these alterations may increase the risk of
arrhythmia, evaluating the proarrhythmic risk of new drugs is
very relevant for the case of glucose-lowering drugs.
Since 2005, potential proarrhythmic risk must be evaluated for
the approval of any new drug, including new anti-hyperglycemic
drugs. Currently, the Thorough QT/QTc (TQT) studies are
performed with premarketing drugs in order to exclude those
that prolong the QT interval (ICH E14). At the same time,
FIGURE 1 | Animal models for diabetes. (A) Type 1 diabetes is induced
by intravenous injection of streptozotocin or alloxane to kill pancreatic beta
cells. Depending on the species, one or more consecutive injections of the
toxic are required. (B)Metabolic models for type 2 diabetes include diet-
induced insulin resistance followed by mild to medium pancreatic toxicity.
Animals are fed with high fat and/or high carbohidrate diet (HFD and HCHD,
respectively) for some weeks to generate insulin resistance and then receive
one or more intraperitoneal injections of low dose streptozotocin to reduce
beta cell mass. (C) Genetically hyperinsulinemic and/or hyperglycemic
animals, lean and obese, spontaneously develop diabetes over time.
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concerns about cardiovascular risk in diabetic patients has guided
the policy of the regulatory agencies to establish the safety of new
glucose-lowering drugs. Therefore, cardiovascular outcome trials
(CVOTs) that evaluate specific cardiovascular endpoints are
being conducted on type 2 diabetic patients (Goldfine, 2008).
Furthermore, the information is being incorporated into the
standards of medical care (Scheen, 2020).
In the preclinical setting, animal models, mainly rodents, but
also guinea pigs, rabbits and dogs, are commonly used for the
study of the diabetic heart. Currently, there are many different
animal models for T1D and T2D (Figure 1). These have been
extensively reviewed, and include spontaneous, transgenic as well
as surgically, chemically and diet-induced models (Masiello,
2006; King, 2012; Al-awar et al., 2016; King and Bowe, 2016).
Most of our knowledge regarding cardiac electrical remodeling in
diabetes derives from studies with animal models of T1D (Magyar
et al., 1992; Shimoni et al., 1994; Casis et al., 2000; Lengyel et al.,
2007; Lengyel et al., 2008). Streptozotocin (STZ) and alloxane are
glucose analogues that destroy pancreatic β-cells (Lenzen, 2008)
and have been, for decades, the choice for inducing experimental
diabetes because the procedure is simple and reliable. T2D has a
different origin and pathophysiology. In humans, it starts with
insulin resistance and eventually there is a loss of functional
β-cells and hyperglycemia. In order to recapitulate this situation,
a number of animal models have been generated using different
strategies. Among them are the leptin-receptor deficient obese
mice (Leprdb/db), the non-obese Goto-Kakizaki (GK) rat with
defective β-cells, the obese Otsuka Long Evans Tokushima Fat rat
(OLETF) or the Zucker diabetic fatty rats (ZDF). In addition,
metabolic models that combine high fat and/or high-
carbohydrate diet with an intraperitoneal low-dose of STZ
(Ionut et al., 2010; Podell et al., 2017) are becoming popular.
Progressive feeding on high caloric food leads to glucose
intolerance and insulin resistance, whereas STZ provides the
loss of functional beta cell mass required establishing diabetes.
In the following section, we will discuss the electrical
characteristics of the diabetic myocardium that may eventually
increase the risk of arrhythmia: from changes in the
electrocardiogram and the action potential, to altered behavior
of sodium, calcium and potassium channels. Then, we will
examine the proarrhythmic safety of antidiabetic drugs and
the recommended treatments for type 2 diabetic patients at
cardiovascular risk.
CARDIAC ELECTRICAL REMODELING
Alterations in the Cardiac Conduction
System in Diabetes
Although diabetic patients frequently have increased heart rate
(Ziegler et al., 2008), diagnosis of bradyarrhythmia and the need
for pacemaker treatment are also more frequent in type 2 diabetic
patients than in control subjects (Rautio et al., 2020). Among the
diabetes-induced electrical disturbances, there is a nodal
dysfunction that may be related to autonomic dysregulation.
In line with this, leptin-receptor deficient db/db mice showed
reduced sinus node recovery time and relative autonomic
denervation that increased the risk of developing arrhythmia
(Soltysinska et al., 2014). On the other hand, there are intrinsic
abnormalities in the sinoatrial node that affect the generation and
conduction of electricity. For example, the non-obese type 2
diabetic Goto-Kakizaki (GK) rats had a reduced expression of
pacemaker channels and connexins. Among others, genes
encoding connexins Cx40, Cx43, and Cx45, as well as the
hyperpolarization-activated cyclic nucleotide-gated channel 4
(HCN4) that drives the funny current If, were downregulated
(Howarth et al., 2018).
Some diabetic patients display slow ventricular depolarization
that is visible in the electrocardiogram as an increase in QRS
duration (Singleton et al., 2020). Reduced expression of HCN4,
connexins and ion channels has also been confirmed in different
regions of the cardiac conduction system in the STZ models of
T1D (Howarth et al., 2007; Watanabe et al., 2012; Zhang et al.,
2019).
Fibroblasts are the most abundant non-cardiomyocyte cells in
atria and ventricles. Cardiac fibroblasts can undergo an activation
process and differentiate to myofibroblasts that express
connexins Cx43 and Cx45. Through these gap junction
proteins, myofibroblasts directly interact with cardiomyocytes
modulating their electrophysiological behavior and reducing
cardiac impulse conduction (Miragoli et al., 2006). Diabetes
favors the phenotype switch to myofibroblasts in the heart.
Thus, differentiation to myofibroblasts is increased in hearts
from STZ-treated and Zucker diabetic rats, which are animal
models of T1D and T2D, respectively (Li et al., 2012a; Fowlkes
et al., 2013).
Prior to the development of fibrosis, diabetes can induce a
lateralization of connexin43 proteins that may impair electrical
coupling. Although normal baseline conduction velocity was
observed in diabetic rats one to 2 weeks after STZ injection,
this normal functioning might be sustained by a robust
ventricular conduction reserve. However, under challenging
conditions like elevated potassium or ischemia, diabetic
ventricles showed larger conduction times compared to
controls (Nygren et al., 2007; Rahnema et al., 2011).
Furthermore, overt impaired conduction velocity may develop
as diabetes progresses. In this sense, long-term type 1 diabetic
rabbits without cardiac fibrosis had decreased conduction already
in basal conditions. Again, stressing the heart with hypo or
hyperkalemia further slowed the velocity. A mechanism
responsible might be the diabetes-induced reduction in the
cardiac sodium current, as reported by electrophysiological
techniques and mathematical modeling (Stables et al., 2014).
Atrial Fibrillation
Diabetes is an independent risk factor for atrial fibrillation (AF)
and diabetic patients have one-third greater risk of incidence of
AF compared with unaffected individuals (Huxley et al., 2012).
Although the underlying pathophysiological mechanisms are not
completely understood, diabetes-induced atrial remodeling
shares some mechanisms with diabetic cardiomyopathy. Atrial
autonomic dysregulation, oxidative stress, fluctuations of glucose
levels and structural and electrical remodeling contribute to the
development of arrhythmia (Goudis et al., 2015; Wang et al.,
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2019). For instance, the above mentioned diabetes-induced
differential expression of conexins, that affects action potential
conduction, might contribute to the development of atrial
fibrillation (Watanabe et al., 2012). Regarding the electrical
remodeling, diabetic Zucker obese rats with higher
susceptibility to AF showed prolonged atrial action potential
duration due to a reduction of the ultrarapid delayed rectifier
and transient outward repolarizing currents (Ikur and Ito) along
with a reduction of the corresponding channel forming proteins
(Fu et al., 2019).
Prolonged QT Interval Duration
The most-studied electrical alteration of the diabetic myocardium is
prolonged ventricular repolarization. Diabetes-induced lengthening of
QT and QTc intervals associates with higher risk of developing
ventricular arrhythmias and sudden cardiac death (Figure 2).
Prolonged QTc was first reported in individuals with diabetic
neuropathy (Bellavere et al., 1988; Chambers et al., 1990; Jermendy
et al., 1990; Ewing et al., 1991) and later, it was also observed in newly
diagnosed type 2 diabetic patients with no apparent complications
(Naas et al., 1998). It is difficult to estimate the prevalence of longer
QTc among diabetics. The different characteristics of the cohorts in
each study and the formula used to adjust the QT for heart rate
(Bazett, Fridericia, Hodges, others) lead to heterogeneous results, with
prevalence estimates ranging from 30 to 66% (Veglio et al., 2002;
Kumar et al., 2004; Li et al., 2012b; Cox et al., 2014; Lu et al., 2017). In
these studies, recruited participants usually exhibited diabetes with
several years of duration and therefore received antidiabetic
medication. Metformin is the first choice to start glycemic control
andmany patients require additional drugs over time (Ferrannini and
DeFronzo, 2015).Most prevalence studies do not differentiate subjects
on monotherapy from those on combined therapy, but the fact is that
antidiabeticmedication does not seem to be efficient to restore normal
QTc values.
Another parameter that analyzes the repolarization is the QT
dispersion or QTd, which reflects the difference between the
longer and the shorter QT interval duration in the 12 leads
electrocardiogram. An increase in the QTd is typically associated
to an increased predisposition to ventricular arrhythmias.
Diabetic patients show increased QTd and heart-rate corrected
QT dispersion (QTdc) compared to non-diabetic subjects in the
absence of other cardiovascular pathologies. Although the
prevalence of severe prolonged QTc (>500 ms) and QTd
(>80 ms) is low (Ninkovic et al., 2016), the presence of
concomitant cardiovascular abnormalities such as left
ventricular hypertrophy or hypertension increased the QT
dispersion in diabetes mellitus (Cardoso et al., 2001).
ION CHANNELS AND CURRENTS IN THE
DIABETIC MYOCARDIUM
The basic electrical activity of the cardiac cells is an action
potential consisting of a rapid depolarization phase followed
by a repolarization phase with a plateau. In 1983, Fein et al.
described for the first time a lengthening of the cardiac action
potential duration (APD) in a rat model of T1D (Fein et al., 1983),
an effect consistently confirmed in rodent and non-rodent
models (Magyar et al., 1992; Casis et al., 2000; Lengyel et al.,
2007; Torres-Jacome et al., 2013). Thus, the APD observed in
animal models of diabetes correlates with the prolonged QTc
duration and increased QTd found in diabetic patients. In
addition, in ventricular myocytes isolated from diabetic rats
APD prolongation was not homogeneous throughout the
heart, and the effect was more pronounced in the
endocardium than in the epicardium (Casis et al., 2000).
Prolonged APD results from diabetes-induced alterations in
the expression and behavior of several ion channels that
conduct depolarizing (sodium and calcium) and repolarizing
(potassium) currents (summarized in Figure 3).
Alterations in the Sodium Current
The protein Nav1.5, encoded by the SCN5A gene, is the cardiac
isoform of the voltage-gated sodium channel, which is
responsible for carrying the sodium current, or INa. Diabetic
rabbits displayed a reduction in the density of the cardiac INa
although the Nav1.5 protein levels were not significantly reduced
(Stables et al., 2014). However, in type 1 diabetic rats, as well as in
culture cells exposed to hyperglycemic conditions, Yu et al.
reported a reduced amount of Nav1.5 channels in the
membrane. The excessive O-linked GlcNAcylation led to
abnormal Nav1.5 aggregation in the cytoplasm and defective
trafficking of the channel to the membrane (Yu et al., 2018).
Nav1.5 channels open during the depolarization phase and then
rapidly inactivate. However, some channels might reopen
creating a persistent or late sodium current or INa,L that
interferes with the repolarization (Zaza and Rocchetti, 2013).
If the contribution of the late component of the INa increases, AP
duration can prolong excessively increasing the risk of
arrhythmia. This might happen in diabetes; in fact, increased
INa,L has been found in type 1 and type 2 (db/db) mice with
FIGURE 2 | Diabetes is a substrate for developing arrhythmia. Example
of electrocardiograms recorded from control and type 2 diabetic rats upon
stimulation with caffeine plus dobutamine. Only diabetic animals develop
arrhythmia under cardiac challenge.
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prolonged QTc (Lu et al., 2013). Moreover, diabetic mice treated
with the INa,L inhibitor GS967 were more resistant to develop
atrial fibrillation under an arrhythmia-inducing protocol than
untreated diabetic animals (Jin et al., 2019). In addition, cultured
cells incubated in high glucose conditions showed an increase in
the late sodium current (Fouda et al., 2020). Different signaling
pathways, metabolites and mechanisms regulate the late sodium
current (Horváth et al., 2020). In diabetic mice, attenuated
insulin/PI3K/Akt signaling increases INa,L, contributing to the
subsequent APD and QTc prolongations (Lu et al., 2013).
Calcium Current and Calcium Handling
The L-type calcium current or ICa-L is a depolarizing current
active during the phase of repolarization of the action potential
and is the current responsible for the maintenance of the plateau
phase. Regarding the ICa-L, experiments with animal models have
yielded confusing results. Some groups found no effects upon the
current amplitude and the biophysical behavior of the calcium
channel (Jourdon and Feuvray, 1993; Tsuchida et al., 1994;
Lengyel et al., 2007; Lengyel et al., 2008) in type 1 diabetic
models. On the contrary, other groups described a reduction
in the current amplitude and a slowing in the current inactivation
kinetics (Horackova and Murphy, 1988; Wang et al., 1995;
Chattou et al., 1999). Finally, some groups reported a
reduction of ICa-L but no effect on the channel behavior. In
this sense, the reduction in the cardiac ICa-L density correlated
with a decreased expression of its channel-forming protein
Cav1.2 in Akita mice, a genetic model of T1D with defective
insulin production, as well as in models of T2D like the db/db
obese mice and Zucker obese rats (Pereira et al., 2006; Lu et al.,
2007; Fu et al., 2019). Electrophysiological recordings of single-
channel activity showed that the biophysical properties of the
calcium channel were similar in control and diabetic animals
(Pereira et al., 2006).
The reason behind these discrepant results is not clear. It
might be related with methodological aspects in current
recordings, such as the patch-clamp configuration or the
charge carrier used in the experiment (Ca2+ or Ba2+). There
could also be intrinsic differences in the diabetic models, for
instance, induced vs. genetic. The experimental conditions for
current recordings are also crucial, since the amplitude of the
L-type calcium current is very sensitive to the intracellular
calcium content. In physiological conditions, L-type calcium
channels inactivate via Ca2+-dependent inactivation, mainly by
the calcium released from the sarcoplasmic reticulum (Pelzer
et al., 1990; Sham, 1997; Kubalová, 2003). Thus, if intracellular
Ca2+ is buffered during the current recording, differences in
current behavior between control and diabetic cardiomyocytes
might not be observed. However, experimental conditions that
preserve the intracellular Ca2+ can differentially affect the
behavior of the ICa-L in control and diabetic cells. In fact,
intracellular calcium handling is altered in the diabetic
myocardium (Allo et al., 1991), showing a characteristic
reduced systolic Ca2+ and an augmented diastolic Ca2+.
Diabetes induces changes in several proteins involved in
calcium handling, what leads to an increase in the cytosolic
(Ca2+). Diabetes prolongs the duration of both the contraction
and the relaxation phases of the cardiac cycle (Regan et al., 1974;
Feuvray et al., 1979; Fein et al., 1980). In the diabetic heart, Ca2+
release from the sarcoplasmic reticulum during systole is
FIGURE 3 | Diabetes affects the depolarizing and repolarizing currents responsible for the cardiac action potential. (A) Action potential depictions of a control and a
diabetic heart (numbers indicate the phase of the AP) showing that diabetes changes action potential shape and prolongs its duration. (B) Summary of the alterations in
the cardiac ion currents and the respective channel-forming proteins obtained in animal models of TD1 and T2D. See text for references.
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depressed, mainly due to a downregulation of Ca2+-releasing
proteins at the SR membrane. In this sense, mRNA and protein
levels of ryanodine receptors (RYRs) are reduced in diabetes and
become fully restored after insulin supplementation (Teshima
et al., 2000; Netticadan et al., 2001). However, more characteristic
of the diabetic myocardium is the diastolic calcium overload,
which is increased about three fold (Allo et al., 1991). Diabetes
increases the opening probability of RYRs and leads to diastolic
Ca2+ leak to the cytoplasm (Singh et al., 2018). In addition,
calcium reuptake to the SR is also compromised because diabetic
cardiomyopathy reduces the expression of the sarcoplasmic
reticulum Ca2+-ATPase (SERCA2) as well as its apparent
affinity for Ca2+ (Teshima et al., 2000; Netticadan et al., 2001),
(Zhong et al., 2001; Abe et al., 2002; Razeghi et al., 2002). As a
result, diabetic cardiomyocytes have higher diastolic calcium
levels caused by a markedly impaired calcium uptake
(Penpargkul et al., 1981; Horackova and Murphy, 1988; Fein
et al., 1990; Golfman et al., 1996). Thus, diabetic cardiomyocytes
have less calcium available for the contraction during systole
together with an excess of diastolic calcium that impairs
relaxation during diastole.
The Repolarizing Potassium Currents
Several potassium currents determine the action potential
repolarization phase. In the human heart these are the
transient outward or Ito, the ultrarapid delayed rectifier or
IKur, the rapid delayed rectifier or IKr, the slow delayed
rectifier or IKs, and the inward rectifier or IK1 (Chiamvimonvat
et al., 2017). Diabetes does not change the inward rectifier, the
current that contributes to the final phase of the repolarization
(Magyar et al., 1992; Casis et al., 2000).
On the contrary, Ito, which is the dominant ventricular
repolarizing current in rodents, is highly affected by T1D. A
reduction in the expression of the channel-forming proteins
Kv4.3 and Kv4.2 and the accessory subunit KChIP2 (Qin
et al., 2001; Lengyel et al., 2007; Torres-Jacome et al., 2013)
caused the reduction in the amplitude of Ito (Magyar et al., 1992;
Shimoni et al., 1994; Xu et al., 1996; Casis et al., 2000). In addition,
diabetes accelerated Ito current inactivation (Magyar et al., 1992;
Casis et al., 2000) due to a reduction in the Kv4.3 channel
phosphorylation by CaMKII (Gallego et al., 2008). This
contributed to the reduction of the total current and the
lengthening of the action potential duration. Regarding IKur,
diabetes reduced the expression of the pore forming protein
Kv1.5, thus inhibiting the current (Casis et al., 2000; Torres-
Jacome et al., 2013).
The delayed rectifiers are virtually absent in rodents; therefore,
they have been analyzed mostly in type 1 diabetic rabbits and
dogs. The amplitude of the slow delayed rectifier IKs was reduced
(Lengyel et al., 2007; Lengyel et al., 2008) which correlated with
the reduced expression levels of the accessory subunit mink,
whereas the pore-forming subunit Kv7.1 was not or little affected
(Lengyel et al., 2007; Zhang et al., 2007). Regarding the rapid
delayed rectifier, most of the studies reported no effect of diabetes
on IKr amplitude and properties (Lengyel et al., 2007; Lengyel
et al., 2008; Torres-Jacome et al., 2013). However, experiments
made in rabbits with long diabetes duration showed significant
reduction of both the IKr amplitude and the expression of its pore-
forming protein ERG (Zhang et al., 2006; Zhang et al., 2007).
A combination of factors can lead to the reduced electrical
activity and expression of cardiac potassium channels. In type 1
diabetic animals, insulin treatment restored some but not all the
altered currents (Zhang et al., 2006; Lengyel et al., 2007). The
impaired metabolic status of the diabetic cells might also affect
protein synthesis. For instance, in vitro activation of the AMP-
dependent protein kinase reduced several K+ repolarizing
currents in a similar fashion than diabetes (Torres-Jacome
et al., 2013). On the other hand, diabetes induced a sterile
inflammation that increased the IL-1b release from cardiac
macrophages and led to the reduction of the Ito (Monnerat
et al., 2016).
The literature regarding cardiac electrical remodeling in
T2D, however, is very limited. A few studies reported a
prolongation of APD and a reduction of the amplitude of the
ventricular Ito current in the genetic models WBN/Kob rats
(Tsuchida et al., 1994; Tsuchida and Watajima, 1997), leptin-
receptor deficient homozygous db/db mice (Shimoni et al.,
2004) or the Otsuka-Long-Evans-Tokushima Fatty rats (Sato
et al., 2014). Similarly, Ito, IKur and ICa-L currents, as well as their
corresponding channel-forming proteins, were reduced in the
atria of Zucker diabetic fatty rats (Fu et al., 2019). Regarding
humans, a study in elderly type 2 diabetic patients (Ashrafi et al.,
2017) showed a reduction of the mRNAs encoding for hERG
and Kir channels responsible for IKr and IK1, and an increase of
the Na+/Ca2+ exchanger (NCX) expression. Although channel
protein levels and current recordings were not assessed and the
study was performed in few, aged and poly-medicated patients,
this is the first work that directly compares the expression of
cardiac channels between diabetic and non-diabetic humans
(Hancox, 2017).
SAFETY ASSESSMENT OF ANTIDIABETIC
DRUGS
Proarrhythmic Safety of New Drugs
Like diabetes, other disorders cause metabolic, endocrine,
immune or autonomic disturbances, providing an
environment that impairs cardiac ion channel function.
Moreover, some drugs can directly inhibit and in some cases
activate ion channels, affecting the overall electric response.
Therefore, the proarrhythmic propensity of drugs is a matter
of concern. Between 1989 and 2003 several drugs were associated
with ventricular arrhythmia, mainly torsade de pointes, and were
withdrawn from themarket [reviewed in Turner et al., 2018]. As a
result, in 2005 the International Council for Harmonization
(ICH) of Technical Requirements for Pharmaceuticals for
Human Use released two guidelines for industry, the non-
clinical S7B and the clinical E14, to evaluate potential
proarrhythmic effects of new drugs.
Non-clinical testing strategy focused mainly on evaluating the
effects of a drug on the hERG channel in vitro, and in
electrocardiographic recordings to analyze ventricular
repolarization (ICH S7B Guideline, 2005). The hERG channel
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encoded by the human ether-a-go-go-related gene conducts the
IKr, the main repolarizing current in humans. The blockade of
hERG channel is responsible for most of the drug-induced QT
prolongations and TdPs because the protein has a peculiar site
that effectively accommodates the binding of drugs and makes it
particularly susceptible to blockade (Sanguinetti and Tristani-
Firouzi, 2006). However, not all the hERG-channel blockers
prolong the QT interval or induce TdP. Some drugs might
have additional effects on other channels that counteract the
lengthening of the repolarization, resulting in normal action
potential and QT interval duration. Furthermore, QTc
prolongation does not necessarily trigger TdP yet may
discontinue compounds from development. Since 2013, the
Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative
works in a new paradigm for assessment of TdP proarrhythmic
risk of new drugs that is not focused exclusively in hERG blockage
and QT prolongation (Sager et al., 2014). Instead, the CiPA
initiative includes: the in vitro assessment of drug effects on
multiple ion channels; the prediction of proarrhythmic risk using
in silico models; the in vitro confirmation of proarrhythmicity in
human stem cell derived ventricular cardiomyocytes; and
electrocardiograms in phase 1 clinical trials (Vicente et al., 2018).
On the other hand, the clinical evaluation of potential
proarrhythmic effects consists on the “Thorough QT/QTc” or
TQT Study, usually performed before phase 3 clinical
development to detect whether the drug has a threshold
pharmacologic effect on prolonging repolarization. In the TQT
studies, healthy voluntaries receive a negative control (placebo); a
positive control (a drug that prolongs the QTc); the drug under
development at the maximum recommended therapeutic dose; and
the drug at supratherapeutic dose to explore the “worst-case
scenario”, for instance, in an impaired clearance of the drug. The
TQT study is negative if the drug does not prolong the mean QT/
QTc interval more than 5ms, which is considered the threshold of
regulatory concern (ICH E14 Guideline, 2015). However, the TQT
study is resource intensive and scientists and regulatory agencies are
discussing alternatives that are more effective, such as the intensive
assessment of ECG parameters in the first-in-human study (Darpo
et al., 2014; ICH E14 Guideline, 2015).
Proarrhythmic Safety of Antidiabetic Drugs
Since metformin, insulin, sulfonylureas or thiazolidinedione were
marketed years before the regulations about arrhythmic safety,
TQT studies did not evaluate these classic antidiabetics. On the
contrary, newer drugs approved after the ICH E14 guideline, such
as semaglutide, have been examined in TQT studies (Demmel
et al., 2018). However, evaluation of glucose lowering drugs is
very challenging since, for instance, changes in blood glucose
concentrations per se may correlate with prolonged QTc (Suys
et al., 2006). The Cardiac Safety Research Consortium discussed
these major confounding factors (Heller et al., 2015). Variations
in glucose, insulin and potassium levels, fasted vs. fed state and
the activation of the autonomous nervous system may all affect
ventricular repolarization, as well as other ECG parameters like
RR interval duration and the T-wave morphology. This
complicates the design and interpretation of TQT studies for
assessing antidiabetic compounds.
Glucose-Lowering Treatment for Patients at
Cardiovascular Risk
On the other hand, although the incidence of cardiovascular
disease (CVD) has declined in both adults with and without
diabetes over the last few decades, diabetic patients still have 2-
fold greater risk of CVD compared with the non-diabetic
population (Fox et al., 2004; Preis et al., 2009). In addition,
studies of the agonist of the peroxisome proliferator-activated
receptor families alpha and gamma muraglitazar, an agonist of
the peroxisome proliferator-activated receptor (PPAR), and the
thiazolidinedione rosiglitazone, concluded an increase in the risk
of death and in the incidence of major adverse cardiovascular
events compared to standard therapy (Nissen et al., 2005; Nissen
and Wolski, 2007). These concerning results precipitated that, in
2008, the FDA issued guidance for industry aimed to ensure that
new antidiabetic therapies for T2D do not increase the CVD risk.
As a result, during pharmacological development of new
antidiabetic drugs, Cardiovascular Outcome Trials (CVOTs)
must be performed on selected type 2 diabetic patients at
higher risk of cardiovascular events (Food and Drug
Administration, 2008). Primary outcome in CVOTs is
typically a composite of death of cardiovascular cause, non-
fatal myocardial infarction and non-fatal stroke. Secondary
outcomes may include hospitalization for heart failure, acute
coronary syndrome and revascularization (Schnell et al., 2016).
Interestingly, diabetes is the only pathology where routine
CVOTs in the absence of safety signals are mandatory.
As with the TQTs, CVOTs were not performed for the old
antidiabetic drugs. Three groups of new drugs: dipeptidyl
peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter
2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1)
receptor agonists have undertaken CVOTs. Detailed
summaries of completed and ongoing studies have been
recently published (Cefalu et al., 2018; Schnell et al., 2019;
Schnell et al., 2020). Although some differences between drugs
exist, CVOTs confirm that the tested drugs fulfill the FDA
requirements because they are not associated with an
unacceptable increase in cardiovascular risk; therefore, all of
them are safe. The GLP1R agonist liraglutide and the SGLT2
inhibitors empagliflozin and, to a lower extent, canagliflozin, have
yielded very positive results. Consequently, the American
Diabetes Association recommended incorporating these drugs
to the standard therapy in T2D patients with established
atherosclerotic cardiovascular disease (Davies et al., 2018).
Furthermore, very recent studies have focused on the potential
protective effect of SGLT2 inhibitors against developing
arrhythmias. In newly diagnosed diabetic patients, SGTL2
inhibitors associates with a reduced risk of new onset
arrhythmia (Chen et al., 2020). Similarly, recent meta-analysis
examining arrhythmia outcomes, like atrial fibrillation and
ventricular tachycardia, found that SGLT2 inhibitors treatment
reduces the risk of cardiac arrhythmias in diabetic patients (Li
et al., 2021). However, in most trials, information regarding pre-
existing arrhythmia and anti-arrhythmic therapy were not
available. More research will be required to determine the best
treatment for those arrhythmic patients who develop diabetes.
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Currently, the ADA recommends the use of either an SGLT2
inhibitor or a GLP-1 receptor agonist to reduce cardiovascular
risk because this treatment is appropriate for many patients
(ADA, 2021). Although both SGLT2i and GLP-1R agonist
could be used in patients with atherosclerotic cardiovascular
disease, SGLT2 inhibitors are recommended in patients with
heart failure or kidney disease (Dardano et al., 2020).
Among the proposed cardioprotective mechanisms are
lowering blood pressure, which may lower cardiac afterload;
improving cardiac metabolism increasing energy production;
reducing inflammation and cytokine release; preventing
adverse cardiac remodeling; reducing sympathetic nerve
activity; improving renal function; improving mitochondrial
dysfunction and improving ionic dyshomeostasis. Thus, the
underlying cardioprotective mechanisms of SGLT2 inhibitors
and GLP-1 receptor agonists remain unclear and might
involve complementary systemic and direct cardiac effects
(recently reviewed in Lahnwong et al., 2018; Dardano et al.,
2020; Lopaschuk and Verma, 2020).
Regarding ionic dyshomeostasis and arrhythmic risk, (Na+)
was elevated in the diabetic myocardium, directly increasing the
risk of sudden arrhythmic death (Lambert et al., 2015).
Empagliflocin inhibits the Na+/H+ exchanger and reduces the
sodium and calcium concentration (Baartscheer et al., 2017).
Another SGLT2 inhibitor, dapagliflozin, reduced the membrane
expression of the Na+/H+ exchanger, the Na+/Ca2+ exchanger and
the L-type calcium channel in db/db mice (Arow et al., 2020). The
resulting reduction of the cytoplasmic (Na+) and (Ca2+) might
reduce the risk of developing potentially lethal arrhythmias. Very
interestingly, in insulin resistant rats dapagliflozin-treatment
improved cardiac repolarization. Daplagliflozin supressed QT
interval and AP prolongation, mainly by restoring the
depressed potassium currents Ito and IK1, but also by reducing
INa (Durak et al., 2018).
CONCLUSION AND FUTURE
PRESPECTIVES
Both T1D and T2D induce a cardiac remodeling that leads to
mechanical dysfunction and/or cardiac arrhythmias. Experiments
with animal models have consistently shown that diabetes alters
the expression and regulation of cardiac ion channels and
transporters, which impairs impulse generation, conduction,
excitation-contraction coupling and myocyte contractility.
Prolonged QTc interval duration persists in a number of treated
diabetic patients, indicating that strict glycemic control is not sufficient
to normalize the electrophysiological disturbances. Available glucose-
lowering drugs that improve cardiovascular prognosis are crucial in
the management of type 2 diabetic patients with established
cardiovascular disease or at high cardiovascular risk. Further
studies are needed to elucidate if cardioprotection includes
electrical remodeling and prolonged repolarization. This could be
of particular interest for patients with diabetes-associated
complications that may increase the risk of arrhythmia.
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